WebFeb 22, 2024 · On January 19, Scandion receives favorable opinion from the European Patent Office on Composition of Matter Patent-application for lead compound SCO-101. … WebScandion Oncology 1.680 følgere på LinkedIn. Scandion Oncology develops drugs that specifically target chemotherapy resistance mechanisms in oncology. Scandion Oncology A/S is a listed Danish biotechnology company with the mission to address one of the most important challenges in modern oncology - the effective treatment of cancer which has …
Scandion Oncology – Q4 & year-end report 2024 - MFN.se
WebScandion Oncology (OMX: SCOL) Scandion Oncology is focused on the development of add-on therapies to reverse chemotherapy resistance in oncology. Lead asset SCO-101 is in a … WebStock analysis for Scandion Oncology A/S (SCOL:FN Stockholm) including stock price, stock chart, company news, key statistics, fundamentals and company profile. tsm the odd one
Scandion Oncology expands clinical development with ...
WebApr 3, 2024 · Scandion Oncology has announced that the Phase Ib PANTAX trial has concluded and reached its primary endpoint. This study (n=22) evaluated SCO-101, the … WebFeb 2, 2024 · Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options, now further upscales its efforts in clinical development by expanding the ongoing CORIST phase II-trial with its lead compound SCO-101 to also include patients in Germany and Spain. WebMar 28, 2024 · The board of directors hereby gives notice of the annual general meeting in Scandion Oncology A/S CVR-no. 38613391 (the "Company") to be held on Wednesday, April 26, 2024, at 2 p.m. (CET), at the Company's address, Fruebjergvej 3, 2100 Copenhagen, Denmark. With the following agenda: 1. Election of chairman of the meeting. tsmthailand